- The Washington Times - Thursday, June 2, 2005

BOSTON (Reuters) — Breast cancer patients who take the Sanofi-Aventis drug docetaxel instead of the older medicine flurouracil cut their risk of death by 30 percent, researchers said yesterday.

Among the women who received docetaxel, ?there’s no group of patients that didn’t benefit, so you can’t pick out someone who’s not a winner from the new treatment,? said study author John Mackey of the Cross Cancer Institute in Edmonton, Canada.

The benefit of the docetaxel combination ?was so large and so striking, it’s turned a lot of heads,? Dr. Mackey said. ?It’s a high-water mark for chemotherapy. It has catapulted the [docetaxel] regimen into being a standard of care.?

The study, published in the New England Journal of Medicine, involved 1,491 women across 20 countries whose tumors had spread to at least one lymph node. Each drug was used in combination with two other commonly used anti-cancer medicines, doxorubicin and cyclophosphamide.

The docetaxel treatment, which already is the standard of care in many cancer centers, reduced the risk of death after five years by 30 percent, bringing the survival rate up to 87 percent, compared to 81 percent for patients using flurouracil.

Docetaxel also reduced the recurrence of cancer. Of the patients put on docetaxel, 25 percent had their breast tumors reappear after five years, compared with 32 percent of those using flurouracil.

Researchers, however, found that the docetaxel combination increased the risk of some serious side effects, such as diarrhea and mouth sores. On the other hand, docetaxel produced significantly less nausea and vomiting than flurouracil.

Another advantage of the docetaxel therapy was that it produced better results, no matter how far the breast cancer cells had spread through nearby lymph nodes.

The flurouracil treatment ?was a reasonable choice during the treatment period of 1995 to 1998, but this may not be the case in 2005,? said Dr. Edith Perez of the Mayo Clinic in Jacksonville, Fla.

But in her editorial in the Journal, Dr. Perez said the side effects and the fact that the treatment was not tested on women older than 70 ?cannot be minimized.?

Docetaxel was approved for use in 1996 and is sold under the brand name Taxotere. Docetaxel is a chemical cousin of the drug Taxol, which has been around for more than a decade, but still remains popular. Which one is better won’t be known until the two are tested against each other.

Copyright © 2018 The Washington Times, LLC. Click here for reprint permission.

The Washington Times Comment Policy

The Washington Times welcomes your comments on Spot.im, our third-party provider. Please read our Comment Policy before commenting.


Click to Read More and View Comments

Click to Hide